Zoetis Inc. (NYSE:ZTS) will participate in the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 10:30 AM ET. Wetteny Joseph, the Chief Financial Officer, will represent the company. Balaji Prasad from Barclays will also be part of the conference call.
Zoetis (ZTS) closed at $170.37 on the most recent trading day, showing an increase of 1.87% from its previous closing price.
Zoetis Inc. (NYSE:ZTS) will participate in the BofA Securities 2025 Animal Health Summit on February 27, 2025, at 1:20 PM ET. The company's CFO, Wetteny Joseph, will be present. Now, I would like to introduce your host, Michael Ryskin from Bank of America.
A great example of this mix today is Zoetis (NYSE: ZTS), a company that focuses on animal healthcare. They support pets, ensure livestock stay healthy, and contribute to fighting the bird flu, which has caused egg prices to rise significantly. Here are the five key reasons why I am increasing my investment in this impressive S&P 500 dividend stock.
It's great when you discover a stock that not only makes you feel good but also has the potential to outperform the market. A prime example of this today is Zoetis, a company that specializes in animal healthcare.
Zoetis has been granted a conditional license for its bird flu vaccine by the US Department of Agriculture to assist in controlling the disease on poultry farms. CEO Kristin Peck shared her thoughts on this development.
The day after revealing quarterly results that did not meet market expectations and led to a drop in stock prices, Zoetis (NYSE: ZTS) saw its shares fall again. In its fourth quarter, Zoetis slightly exceeded analysts' profit predictions and met their revenue forecasts. Major players like Morgan Stanley and Bank of America Securities were among those significantly impacting the situation.
The day after releasing quarterly results that did not meet market expectations and caused a drop in stock prices, Zoetis (ZTS -4.49%) shares fell again. By the end of trading on Friday, they had decreased by 4%, largely because several analysts lowered their price targets.
On Friday, Zoetis announced that its bird flu vaccine has been given a conditional license by the U.S. Department of Agriculture for use in chickens and other poultry.
Kristin Peck, the CEO of Zoetis, appears on 'Closing Bell Overtime' to discuss their Avian Flu vaccine, the effects of tariffs, and other topics.